Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01272999 · ClinicalTrials.gov registry record
Impact of Prevnar 13 on Ear Infections in Children
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 391
- Enrollment target
NCT01272999: Completed study, sponsored by Pfizer.
NCT01272999 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 391 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01272999 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 391 participants
- Enrollment target
Study Summary
Prevnar (7 valent pneumococcal conjugate vaccine \[7vPnC\]) has been shown to be effective against ear infections in children. Prevnar 13 is a new vaccine that is similar to Prevnar. It is expected that the effectiveness of Prevnar 13 against ear infections in children will be similar to that observed following Prevnar. Pfizer has committed to conduct a postmarketing study of the impact of Prevnar 13 in reducing ear infections among children.
Primary Outcome
The distribution of S pneumoniae serotypes isolated from MEF samples from children in the target population for vaccination over the surveillance year 1 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (3, 7F, 19A, 19F) and not included in Prevnar 13 (6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38) along with total (both included and not included), clumps and missing or non-viable were
Interventions
- OTHER No intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 391 participants |
| Start Date | 2010-05-21 |
| Est. Completion | 2013-12-19 |
What the finished NCT01272999 record still lists
NCT01272999 is an observational study that tracks outcomes without assigning an intervention. The registered 391 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.
NCT01272999 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01272999 about?
NCT01272999 is a clinical study titled "Impact of Prevnar 13 on Ear Infections in Children". Prevnar (7 valent pneumococcal conjugate vaccine \[7vPnC\]) has been shown to be effective against ear infections in children. Prevnar 13 is a new vaccine that is similar to Prevnar. It is expected that the effectiveness of Prevnar 13 against ear infections in children will be similar to that observ...
What is the current status of trial NCT01272999?
This trial is currently completed. The enrollment target is 391 participants. The study started on 2010-05-21. Estimated completion is 2013-12-19.
What interventions are being tested in trial NCT01272999?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT01272999?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06397703 · 392 participants · Phase 2
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
- NCT06625775 · 392 participants · Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- NCT07220967 · 392 participants · Phase 4
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
- NCT07290036 · 392 participants · Phase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI